XNK Therapeutics presented two posters at the NK2023 conference in Oslo
XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20[th] Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.XNK Therapeutics participate at NK2023 in Oslo and present the latest research relating to the company’s leading natural killer (NK) cell therapies. Two abstracts have been accepted for presentation at the meeting. The poster on BC shows the feasibility of expanding autologous NK cells from peripheral blood mononuclear cells (PBMCs) from BC patients.